Ross Mitchell named artificial intelligence officer at Moffitt

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Ross Mitchell has joined Moffitt Cancer Center as the artificial intelligence officer.

In this new role, he will lead the cancer center’s efforts to develop digital tools and technologies that utilize computer science to improve the efficiency and quality of cancer care.

Mitchell is also a senior member of Moffitt’s Department of Biostatistics and Bioinformatics and will collaborate with fellow research faculty to optimize projects utilizing artificial intelligence applications.

“Data science is a growing area in cancer research and care. Through the analysis of data, we can better predict outcomes to assist with informed decision-making. Mitchell will help Moffitt identify those business and clinical opportunities where predictive analytics, machine learning and other advanced technologies can be used to improve our patient experience,” said Dana Rollison, vice president, chief data officer and associate center director of Data Science at Moffitt. “He will also bring this skillset to our research enterprise.”

Mitchell comes to Moffitt from the Mayo Clinic in Scottsdale, where he led multiple medical imaging informatics initiatives such as the application of machine learning in brain tumor imaging.

Table of Contents

YOU MAY BE INTERESTED IN

Just consider for a minute if this was the first year of running your lab, if you were on the job market as a physician or scientist right now, if you were a resident contemplating a career in cancer research after fellowship, if you were a graduate student or postdoc, if you were an undergraduate or a technician who was looking toward graduate school.
The immune system can be a powerful tool to control cancer. Immune cells within our body detect cancer cells and release payloads that kill them. Transformative science in the last decade has led to the development of therapies that enhance the ability of our immune cells to carry out this function. These therapies, including checkpoint blockade and CAR-T cells, have been lifesaving for many patients that before had untreatable cancer. But, sadly, a majority of patients with advanced solid tumors still succumb to their disease. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login